This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Poon ML, Fox PS, Samuels BI, O’Brien S, Jabbour E, Hsu Y et al. Allogeneic stem cell transplant in patients with chronic lymphocytic leukemia with 17p deletion: consult-transplant versus consult- no-transplant analysis. Leuk Lymphoma 2014; 56: 1–5.
Wiestner A . The role of B-cell receptor inhibitors in the treatment of patients with chronic lymphocytic leukemia. Haematologica 2015; 100: 1495–1507.
de Rooij MFM, Kuil A, Kater AP, Kersten MJ, Pals ST, Spaargaren M . Ibrutinib and idelalisib synergistically target BCR-controlled adhesion in MCL and CLL: a rationale for combination therapy. Blood 2015; 125: 2306–2309.
Dreger P, Schetelig J, Andersen N, Corradini P, Van Gelder M, Gribben J et al. Managing high-risk CLL during transition to a new treatment era: stem cell transplantation or novel agents? Blood 2014; 124: 3841–3849.
Dreger P, Dohner H, Ritgen M, Bottcher S, Busch R, Dietrich S et al. Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the GCLLSG CLL3X trial. Blood 2010; 116: 2438–2447.
Byrd JC, Furman RR, Coutre SE, Burger JA, Blum KA, Coleman M et al. Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib. Blood 2015; 125: 2497–2506.
Jaglowski SM, Byrd JC . Novel therapies and their integration into allogeneic stem cell transplant for chronic lymphocytic leukemia. Biol Blood Marrow Transplant 2012; 18(1 Suppl): S132–S138.
Tam CS, Stilgenbauer S . How best to manage patients with chronic lymphocytic leuekmia with 17p deletion and/or TP53 mutation? Leuk Lymphoma 2015; 56: 587–593.
Link CS, Teipel R, Heidenreich F, Rücker-Braun E, Schmiedgen M, Reinhardt J et al. Durable responses to ibrutinib in patients with relapsed CLL after allogeneic stem cell transplantation. Bone Marrow Transplant 2016; 51: 793–798.
Rozovski U, Benjamini O, Jain P, Thompson PA, Wierda WG, O’Brien S et al. Outcomes of patients with chronic lymphocytic leukemia and Richter’s transformation after transplantation failure. J Clin Oncol 2015; 33: 1557–1563.
Coutre S, O’Brien S, Byrd JC, Hillmen P, Brown JR, Dyer MJS et al. Safety and efficacy of ibrutinib in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma who have undergone prior allogeneic stem cell transplant. Blood 2014; 124: 4697.
Dubovsky JA, Flynn R, Du J, Harrington BK, Zhong Y, Kaffenberger B et al. Ibrutinib treatment ameliorates murine chronic graft-versus-host disease. J Clin Invest 2014; 124: 4867–4876.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Montserrat, E., Delgado, J. CLL: ibrutinib and transplantation ride together. Bone Marrow Transplant 51, 769–770 (2016). https://doi.org/10.1038/bmt.2016.118
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/bmt.2016.118